Amgen
Search results
After the merger, Biogen Idec became the 3rd largest Biotechnology company in the world. [9] Following shifts in research core areas, the company has since shortened its name, reverting to simply Biogen. [10]
Biogen is advancing a pipeline of potential therapies across neurology, neuropsychiatry, specialized immunology and rare disease and remains acutely focused on its purpose of serving humanity through science while advancing a healthier, more sustainable and equitable world.
Aug 19, 2022 · Transforming Medicine Together. Paul Chinn leads a Biogen Idec team in groundbreaking cancer research. Read how Paul’s work has helped Rick. Eastern Cooperative Oncology Group (ECOG) Phase III Trial Of Rituxan Maintenance Therapy In Indolent Non-Hodgkin’s Lymphoma Reaches Pre-Specified Efficacy Endpoint Early.
Biogen is a leading global biotechnology company that pioneers science and drives innovations for complex and devastating diseases. Biogen is advancing a pipeline of potential therapies across neurology, neuropsychiatry, specialized immunology and rare disease and remains acutely focused on its purpose of serving humanity through science while ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Effective today, Biogen Idec is known simply as Biogen (NASDAQ: BIIB). The company has introduced a new corporate identity and logo that reflect both its evolution and focus on bringing forth new therapies in areas of high unmet need – while honoring Biogen’s scientific heritage and legacy as a pioneer in ...
With a strong focus on difficult-to-treat diseases, our pipeline is focused on research in therapeutic areas where we believe we have the best opportunity to deliver transformational medicines to patients and protect public health.
Biogen Idec intends to expand its global leadership in MS by maximizing the potential of AVONEX® (interferon beta-1a) and TYSABRI® (natalizumab) and aggressively bringing forward its promising MS pipeline, including fampridine, BG-12, PEGylated interferon, daclizumab and anti-LINGO.The company will aggressively pursue emerging opportunities ...
